SPIROVANT
Spirovant is focused on changing the course of cystic fibrosis and other pulmonary diseases. Their gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.
SPIROVANT
Industry:
Biotechnology Genetics Medical
Founded:
2016-01-01
Address:
Pausa, Sachsen, Germany
Country:
Germany
Website Url:
http://www.spirovant.com
Total Employee:
11+
Status:
Active
Contact:
+267 244 8206
Email Addresses:
[email protected]
Total Funding:
4.73 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API WordPress Google Maps SSL By Default Font Awesome Microsoft Exchange Online
Similar Organizations
ALPHELYS
ALPHELYS designs and develops instruments, software, and reagents for pathology and cytogenetics markets.
Pathway Genomics
Pathway Genomics is a CAP accredited global clinical lab offering genetic tests for cancer risk, drug responses, and other conditions.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Spirovant
Small Business Innovation Research
Small Business Innovation Research investment in Grant - Spirovant
Official Site Inspections
http://www.spirovant.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Spirovant"
About Us - Spirovant
At Spirovant, we are passionate about “CURES” – collaboration, urgency, respect, empowerment and science. Spirovant Values. ... AstraZeneca’s global biologics organization, where he provided strategic direction as Chair of the …See details»
Spirovant - Crunchbase Company Profile & Funding
Organization. Spirovant . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Spirovant Sciences is developing novel gene …See details»
Spirovant Sciences, Inc. Overview | SignalHire Company Profile
Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors. …See details»
Spirovant - Leadership Team - The Org
The Leadership Team at Spirovant Sciences is responsible for shaping the strategic direction and overall vision of the company as it develops innovative gene therapies for cystic fibrosis and …See details»
Spirovant Launches State-of-the-Art Laboratory and …
May 18, 2022 The facilities are located in the center of Philadelphia’s thriving life sciences corridor. Philadelphia, PA, May 17, 2022 – Spirovant Sciences, a gene therapy company developing treatments for inherited respiratory diseases, …See details»
Spirovant - Funding, Financials, Valuation & Investors - Crunchbase
Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Org Chart Spirovant - The Official Board
Organizational Chart of Spirovant. Spirovant www.spirovant.com. has 6 executives - and belongs to Sumitomo Pharma America +1 267 244 8206; Add an executive. Spirovant News . Anything …See details»
Spirovant - Crunchbase
Spirovant Sciences, Slingshot Biosciences, Pathway Genomics, ALPHELYS, and Biogenet are all involved in the biotechnology and genetic testing sector. Spirovant Sciences focuses on gene …See details»
Spirovant Sciences, Inc. Company Profile | Philadelphia, PA ...
Find company research, competitor information, contact details & financial data for Spirovant Sciences, Inc. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
Spirovant Sciences Company Profile 2024: Valuation, Investors ...
The current revenue for Spirovant Sciences is . Who are Spirovant Sciences’s investors? Cystic Fibrosis Foundation , Emily's Entourage , Militia Hill Ventures , Roivant Sciences , and …See details»
Spirovant Launches State-of-the-Art Laboratory and Headquarters
May 16, 2022 Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company's current investigational gene therapy …See details»
Spirovant Sciences Company Profile - Office Locations ... - Craft
Spirovant Sciences is a company focused on the development of gene therapies for treating and curing cystic fibrosis and other lung diseases. It advances programs with both AAV (adeno …See details»
Spirovant Continues Rapid Growth with New Headquarters and
Jan 26, 2021 Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company's current investigational gene therapy …See details»
Spirovant Launches State-of-the-Art Laboratory and… - Science …
PHILADELPHIA, May 16, 2022 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis (CF), announced today …See details»
Spirovant - Contacts, Employees, Board Members, Advisors
Organization. Spirovant . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Contacts 27. ...See details»
Spirovant Sciences - Overview, News & Similar companies
Apr 26, 2022 Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company's current investigational gene therapy …See details»
Science – Spirovant
Spirovant’s lead candidate SP-101 is optimized to overcome historical barriers. SP-101 is composed of a novel AAV capsid, AAV2.5T, that has been selected for its high tropism to the …See details»
News - Spirovant
Spirovant Sciences, Inc. 3675 Market Street, Suite 900 Philadelphia, PA 19104 [email protected] (267) 244-8206See details»
Newsroom - Spirovant
Spirovant’s SP-101 pre-clinical data demonstrates great promise for individuals with cystic fibrosis (CF) who do not benefit from small molecule modulators November 3, 2022 New pre-clinical …See details»